Navigation Links
Antigen Discovery Inc. Awarded a SBIR Phase II Grant to Commercialize Novel Antigens for Serodiagnostic Products and Vaccine Development
Date:7/3/2008

IRVINE, Calif., July 3 /PRNewswire/ -- Antigen Discovery Inc. ("ADI", formerly ImmPORT Therapeutics Inc.), a leader in high throughput antigen/biomarker discovery using advanced genomics and proteomics tools, announced today that the Company was awarded a Phase II SBIR from the National Institute of Allergy and Infectious Diseases (NIAID) and the National Center for Research Resources (NCRR). The $3 million grant will fund efforts to further develop ADI's protein microarray based serodiagnostic platform for applications in biodefense and emerging infectious diseases. ADI will collaborate with investigators at the Proteomics Core facility of the Pacific Southwest Regional Center of Excellence (PSW RCE), located at the University of California, Irvine.

"The major bottleneck that limits the translation of readily available genomic information into the development of next generation diagnostics, vaccines and therapeutics, is the continued lack of effective antigen and biomarker discovery tools," said Dr. Xiaowu Liang, CEO of ADI. "We are grateful that the SBIR program continues to fund ADI and our UCI collaborators in the further development of this exciting new technology platform that truly revolutionizes the screening and detection of disease markers."

"The focus of this grant is to commercialize some of the broad applications of the platform technology that were developed during previous funding phases. The establishment of a Good Manufactuing Practices (GMP) facility, and a Clinical Research Lab will enable us to offer diagnostic products and services to physicians, point of care facilities, developers of novel vaccines, and pharmaceutical researchers," added Dr. Huw Davies, the Principal Investigator on the SBIR grant. "By using our novel protein array systems and statistical algorithms, we can rapidly discover antigen sets that will provide serological tests that discriminate between different infections, or even between different stages of the same infection."

About Antigen Discovery Inc.

Antigen Discovery Inc. (formerly ImmPORT Therapeutics Inc.) is a privately held biotech company with innovative technologies that offer unprecedented advantages for the rapid development of safer and more effective vaccines and diagnostic products. The Company's high throughput proteome microarray chip fabrication and screening platform provides an order of magnitude of improvement over current antigen/biomarker discovery technologies. The technology also has potential applications in the identification of markers for autoimmune disease and cancer.


'/>"/>
SOURCE Antigen Discovery Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
2. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
3. Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBCs Drug Discovery & Development of Innovative Therapeutics Conference
4. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
5. Discovery by UC Riverside physicists could enable development of faster computers
6. Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology
7. Oncomine(TM) Again Key to Prostate Cancer Discovery
8. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
9. Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs
10. WuXi PharmaTech (NYSE: WX) Appoints Dr. Peng Wang as VP of Discovery Biology
11. Genetic Engineering and Biotechnology News (GEN) Reports on Mass Spec in Drug Discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... 2016  The Maryland House of Delegates and House ... University of Maryland School of Medicine Dean E. ... Maryland Medical System President and CEO Robert Chrencik ... highest honor given to the public by the leader ... Reece and Mr. Chrencik for their contributions to ...
(Date:2/10/2016)... Feb. 10, 2016  IsoRay, Inc. (NYSE MKT: ISR), ... and medical radioisotope applications for the treatment of prostate, ... announced its financial results for the second quarter and ... 2015. --> --> ... of fiscal 2016, which ended December 31, 2015, a ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... attend the International Society of Pharmaceutical Engineering (ISPE) Rocky Mountain Chapter 21st Annual ... is expecting to fill more than 100 tables for its annual event, which ...
(Date:2/10/2016)... ... February 10, 2016 , ... Curoverse ... Azure. On Azure, Arvados provides capabilities for managing and processing genomic and health ... Azure from major institutions collecting and analyzing genomic data,” said Adam Berrey chief ...
Breaking Biology Technology:
(Date:2/1/2016)... YORK , Feb. 1, 2016  Today, the ... Association (AHA) announced plans to develop a first of ... computing power of IBM Watson. In the first application ... AHA, IBM (NYSE: IBM ), and Welltok will ... and health assessments with cognitive analytics, delivered on Welltok,s ...
(Date:1/27/2016)... CHESTER, Ohio , Jan. 27, 2016  Rite ... supplier based in West Chester, Ohio ... their award winning service staff, based in ... technical capacity and ability to provide modifications, installations and ... John Dovalina , CEO of PLUS, commented, "PLUS has ...
(Date:1/22/2016)... DUBLIN , January 22, 2016 ... has announced the addition of the  ... to their offering. --> ... of the  "Global Behavioral Biometric Market ... --> Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ...
Breaking Biology News(10 mins):